Elderly patients with drug anavar administered in the same dose as adults.
When expressed violations of the liver and / or kidney creatinine clearance <50 mL / min or serum creatinine concentration in the blood of more than 300 mmol / L): 125 mg 1 time per day.
Dyspeptic disorders (loss of appetite, nausea, diarrhea, feeling of fullness, abdominal pain); allergic skin reactions (rash, hives); musculoskeletal reactions (arthralgia, myalgia), worsening of current systemic lupus erythematosus.
Taste disturbance, including their loss (recovery occurs within a few weeks after cessation of treatment).
Very rarely: hepatobiliary disorders (cholestatic jaundice), malignant exudative erythema (Stevens – Johnson), toxic epidermal necrolysis (Lyell’s syndrome), anaphylactoid reactions, agranulocytosis or thrombocytopenia, neutropenia, lymphopenia.
Symptoms: nausea, vomiting, anavar pain in the lower abdomen in the epigastric region.
Treatment: gastric lavage, followed by the appointment of activated carbon and / or symptomatic therapy.
Interaction with other drugs.
It inhibits CYP2D6 isoenzyme and inhibits the metabolism of drugs such as tricyclic antidepressants and selective serotonin uptake blockers (eg. Desipramine, fluvoxamine), β1-blockers (metoprolol, propranolol), antiarrhythmics (flecainide, propafenone), MAO- The inhibitor (selegiline) and antipsychotics (e.g., chlorpromazine, haloperidol).
Medications – inducers of enzymes (. Eg rifampicin) may accelerate the excretion of terbinafine from the body.
Medications – anavar inhibitors (. Eg cimetidine) may slow the metabolism and excretion of terbinafine from the body. With the simultaneous use of these drugs may require dose adjustment of terbinafine.
Possible disruption of the menstrual cycle while taking terbinafine and oral contraceptives.
It reduces the clearance of caffeine by 21% and prolongs its half-life by 31%. It does not affect the clearance of phenazone, digoxin, warfarin.
When combined with ethanol or drugs having hepatotoxic effect, there is a risk of liver disease drug.
Irregular use or premature discontinuation of terbinafine treatment lead to relapse.
On the duration of therapy can influence factors such as the presence of comorbidities, the state of the nails in the beginning of treatment.
If after 2 weeks of treatment, no improvement in the state, it is necessary to re-determine the causative agent and its sensitivity to the drug.
Systemic application in onychomycosis is anavar justified only in case of total destruction of the majority of the nails, the presence of pronounced subungual hyperkeratosis, ineffectiveness of previous local therapy.
In the treatment of onychomycosis clinical response is usually seen after a few months after mycological cure and treatment discontinuation rate due to the rate of regrowth of healthy nail. Removal of the nail plate in the treatment of onychomycosis of brushes for 3 weeks and onychomycosis stop for 6 weeks is required.
If you have severe renal insufficiency (creatinine clearance less than 50 ml / min or creatinine in the blood of more than 300 mmol / l), with abnormal liver function the dose of terbinafine should be halved.
In the presence of liver disease may be the clearance of terbinafine is reduced.
With reduced liver function is assigned half of the adult dose. During treatment is necessary to control the level of liver transaminases in the serum. In rare cases, after 3 months of treatment there is cholestasis and hepatitis. When liver function disorders symptoms (fatigue, persistent nausea, loss of appetite, abdominal pain, jaundice, dark urine or stool, colorless) the drug should be discontinued.
Appointment of terbinafine patients with psoriasis requires more diligence, because In very rare cases, terbinafine may trigger psoriasis flare.
In the treatment of terbinafine should comply with the general rules of hygiene to prevent the possibility of re-infection through underwear and shoes. During the treatment (2 weeks.) And finally antifungal treatment is necessary to produce shoes, socks and stockings. Effects on ability to drive and working mechanisms: terbinafine does not affect anavar the ability to drive and perform work requiring high concentration.